Navigation Links
Enigma Diagnostics Announces Patent Licence With Applied Biosystems
Date:10/22/2008

PORTON DOWN, England, Oct 22 /PRNewswire/ -- Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today that it has signed a third licence agreement with Applied Biosystems.

The licence provides Enigma with access to claims of US Patent No. 5,928,907 that describe methods for monitoring nucleic acid amplification in real-time. This is the first such licence Applied Biosystems has granted to the method claims of the '907 patent.

This complements Enigma's existing licence under certain patents owned by Applied Biosystems for real-time PCR thermal cyclers.

Financial terms were not disclosed.

Contacts

UK Contact:

Enigma Diagnostics

Deborah Cordingley

deborah.cordingley@enigmadiagnostics.com

+44 1980 590131

US Contact:

Richard Lewis Communications, Inc.

212-827-0020

Gregory Tiberend - Media

gtiberend@rlcinc.com

Megan Dubrowski - Media

mdubrowski@rlcinc.com

Cecelia Heer - Investors

cheer@rlcinc.com

Notes to editors:

About Enigma Diagnostics Limited

Enigma Diagnostics Limited is a private UK based company specialising in developing the next generation of rapid molecular diagnostic instrument platforms for decentralised and point-of-care settings.

Enigma's innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for field-based, decentralised and point-of-care tests providing results from a raw sample in less than 45 minutes.

The Company is targeting a number of multi-billion pound markets, core among which are the Clinical and high value Applied Markets. Enigma's commercialisation strategy is to maximise revenues from a continuous flow of market leading rapid diagnostic point-of care and in-field instrument and assay platforms, derived from its broad Intellectual Property portfolio of issued and filed patents. Enigma will partner with market leaders where global penetration of markets is required and where appropriate will build an in-house sales and marketing capability to direct distribution of its products.

Enigma has an exclusive licence from the Defence Science Technology Laboratory to a portfolio of patents, which represent over 15 years of UK Ministry of Defence funded research and has licences from Applied Biosystems and Celera Licences for the commercialisation of real-time PCR instruments. Enigma's R&D activities have generated a portfolio of over 50 plus worldwide patent families dedicated to real-time PCR and wider molecular technologies. Many of these patents are granted across a range of core commercial territories including US, EU and Japan with more extensive filing and grants across a number of other key territories.

For more information visit http://www.enigmadiagnostics.com


'/>"/>
SOURCE Enigma Diagnostics Limited
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Enigma Diagnostics Announces an Award of GBP 1.8 Million From UK Government
2. Enigma Signs Real-Time PCR Licences With Applera
3. Enigma Diagnostics to Develop Clinical Diagnostics Platform for UK National Chlamydia Screening Programme
4. Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
5. Golub Capital Provides Debt Financing to Support the Acquisition of DNA Diagnostics Center, Inc. by MTS Health Investors, LLC
6. Exiqon A/S Announces U.S. Subsidiary Name Change From Oncotech, Inc. to Exiqon Diagnostics, Inc.
7. Axial Biotech Appoints Retired Roche Diagnostics Executive to Board
8. Pathwork Diagnostics Announces Key Additions to Management Team
9. InformationWeek Puts Roche Diagnostics on Top 500 Innovative Tech Users List
10. Fujirebio Diagnostics Named One of the Best Places to Work in Pennsylvania
11. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016 Australian-US drug discovery ... announced today the appointment of a new Chairman, Mr ... Carmine , effective immediately. James Garner , ... Executive Director and former Acting CEO, Mr Iain Ross ... Non-Executive Director. --> James Garner , has also ...
(Date:2/4/2016)... ... 04, 2016 , ... Shimadzu Scientific Instruments will showcase several ... and poster sessions, and present on the analysis of mycotoxins and medical cannabis ... to 10 at the Georgia World Congress Center in Atlanta, Georgia. , ...
(Date:2/4/2016)... and MENLO PARK, Calif. , Feb. ... ("DelMar" and the "Company"), a biopharmaceutical company focused on the ... it will present at the 18 th Annual ... 2016 at 10:00 a.m. EST in New York, ... president and CEO, will provide an update on the ongoing ...
(Date:2/4/2016)... Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: ... China , today announced that the ... February 4, 2016 a preliminary non-binding proposal letter, dated ... V-Ming ( Shanghai ) Investment Holdings Co., ... Shenzhen ) Fund Management Co., Ltd., Beijing ...
Breaking Biology Technology:
(Date:1/20/2016)... SAN JOSE, Calif. , Jan. 20, 2016 ... leading developer of human interface solutions, today announced ... touch controller solution for wearables and small screen ... appliances such as printers. Supporting round and rectangular ... the S1423 offers excellent performance with moisture on ...
(Date:1/11/2016)... , Jan. 11, 2016 Synaptics Incorporated ... interface solutions, today announced that its ClearPad ® ... (TDDI) products won two separate categories in the 8 ... Innovator and Best Technology Breakthrough. The Synaptics ® ... a simplified supply chain, thinner devices, brighter displays and ...
(Date:1/7/2016)... -- Various factors have contributed to the rise ... and biosimilars. Some of these factors include the ... for cost-effective alternatives, growing burden of chronic diseases, ... of their corresponding patented biologic drugs, and are ... efficacy. The global biosimilars market is estimated to ...
Breaking Biology News(10 mins):